iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

UnknownOBSERVATIONAL
Enrollment

475

Participants

Timeline

Start Date

January 15, 2020

Primary Completion Date

January 20, 2021

Study Completion Date

December 31, 2021

Conditions
Glaucoma, Open-Angle
Trial Locations (24)

12159

Glaucoma Consultants of the Capital Region, Slingerlands

24016

Vistar Eye Center, Roanoke

30260

Clayton Eye Clinical Research, LLC., Morrow

33603

International Research Center, Tampa

33904

Argus Research, Cape Coral

34285

Center for Sight, Venice

48201

Kresge Eye Institute / Wayne State University, Detroit

53405

The Eye Center of Racine and Kenosha, Racine

60467

Arbor Center for Eye Care, Orland Park

60619

Chicago Eye Specialists, Chicago

64055

Discover Vision Centers, Independence

66213

Stiles Eyecare Excellence, Overland Park

72704

Vold Vision, PLLC, Fayetteville

73112

Oklahoma eye Surgeons, PLLC, Oklahoma City

76102

Ophthalmology Associates, Fort Worth

78229

Parkhurst Nuvision, San Antonio

R and R Eye Resarch, LLC, San Antonio

78731

Keystone Research, Austin

80528

Eye Center of northern Colorado, PC, Fort Collins

85306

Arizona Advanced Eye Research Institute, Glendale

95401

North Bath Eye Associates, Inc., Santa Rosa

99204

Spokane Eye Clinical Research, Spokane

01523

D'Ambrosio Eye Care, Lancaster

07079

Northern New Jersey Eye Institute, South Orange

Sponsors
All Listed Sponsors
lead

Glaukos Corporation

INDUSTRY

NCT04624685 - iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study | Biotech Hunter | Biotech Hunter